See analyst estimates and all valuation multiples for Biopharmaceuticals
Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
$705B | 14.0x | 36.0x | |
$397B | 6.9x | 15.3x | |
$371B | 4.1x | 11.5x | |
$305B | 6.6x | 13.4x | |
$272B | 3.7x | 9.3x | |
$238B | 4.3x | 10.6x | |
$238B | 4.1x | 12.1x | |
$218B | 3.4x | 8.0x | |
$194B | 5.7x | 10.0x | |
$174B | 2.8x | 7.1x | |
$143B | 5.0x | 11.8x | |
$140B | 2.8x | 9.5x | |
$134B | 2.8x | 12.5x | |
$106B | 9.4x | 42.3x | |
$91.9B | 2.2x | 6.3x | |
$85.2B | 5.5x | 16.6x | |
$78.5B | 9.6x | 19.4x | |
$76.4B | 8.2x | 19.2x | |
$72.8B | 2.3x | 8.9x | |
$69.7B | 2.9x | 10.1x | |
$63.3B | 1.2x | 5.7x | |
$53.8B | 6.4x | 22.7x | |
$45.6B | 7.3x | 25.4x | |
$41.8B | 10.4x | 40.9x | |
$40.8B | 3.1x | 15.9x | |
$35.4B | 2.1x | 7.2x | |
$24.8B | 8.9x | 28.2x | |
$23.8B | 1.7x | 5.4x | |
$23.7B | 1.5x | 6.4x | |
$23.2B | 2.1x | 10.4x | |
$22.1B | 2.2x | 6.5x | |
$22.1B | 2.3x | 6.7x | |
$21.1B | 1.6x | 8.4x | |
$19.6B | 6.9x | 7.4x | |
$16.5B | 2.0x | 8.1x | |
$14.7B | 23.7x | 45.6x | |
$14.3B | 5.2x | 14.0x | |
$13.9B | 7.9x | 21.2x | |
$13.4B | 4.1x | 16.1x | |
$13.1B | 149.3x | 309.1x | |
$13.0B | 9.5x | 29.1x | |
$12.3B | 2.2x | 15.7x | |
$12.0B | 4.3x | 11.9x | |
$11.8B | 8.0x | 30.4x | |
$11.6B | 3.0x | 11.3x | |
$11.1B | 4.5x | 17.0x | |
$11.0B | 4.1x | 17.6x | |
$10.8B | 1.9x | 10.8x | |
$10.6B | 1.7x | 5.4x | |
$10.3B | 3.8x | 12.9x | |
$9.8B | 6.9x | 268.3x | |
$9.8B | 36.7x | -317.7x | |
$9.6B | 3.1x | 7.5x | |
$9.4B | 2.4x | 6.6x | |
$9.3B | 1.6x | 12.4x | |
$8.9B | 23.9x | -528.5x | |
$8.8B | 5.0x | 14.9x | |
$8.8B | 2.9x | 7.1x | |
$8.7B | 2.6x | 7.4x | |
$8.4B | 2.3x | 10.6x | |
$8.1B | 2.0x | 8.6x | |
$7.4B | 0.2x | 3.4x | |
$7.4B | 9.7x | 36.6x | |
$7.3B | 1.4x | 11.0x | |
$7.0B | 1.7x | 7.1x | |
$6.9B | 6.3x | 10.0x | |
$6.8B | 2.1x | 7.9x | |
$6.8B | 4.4x | 22.2x | |
$6.7B | 1.7x | 8.9x | |
$6.5B | 15.0x | 20.2x | |
$6.5B | 1.9x | 8.2x | |
$6.2B | n/a | n/a | |
$6.2B | n/a | n/a | |
$6.2B | 3.4x | 16.3x | |
$5.8B | 3.8x | 56.7x | |
$5.7B | 4.6x | 13.4x | |
$5.6B | 2.6x | 9.4x | |
$5.3B | 11.9x | 39.0x | |
$5.2B | 8.1x | 27.9x | |
$5.1B | 2.0x | 5.5x | |
$5.0B | 5.7x | 14.7x | |
$4.9B | 2.6x | 11.5x | |
$4.9B | 1.7x | 7.6x | |
$4.8B | 12.2x | 53.2x | |
$4.8B | 10.4x | 24.9x | |
$4.6B | 2.9x | 16.1x | |
$4.6B | 6.0x | 20.7x | |
$4.6B | 1.9x | 8.5x | |
$4.6B | 1.4x | 6.0x | |
$4.4B | 8.0x | 27.8x | |
$4.3B | 2.9x | 11.1x | |
$4.0B | 9.2x | 24.5x | |
$4.0B | 2.9x | 10.4x | |
$3.9B | 8.0x | 32.5x | |
$3.8B | 6.0x | 14.6x | |
$3.7B | 1.9x | 12.4x | |
$3.7B | n/a | n/a | |
$3.6B | 4.5x | 28.5x | |
$3.6B | 13.5x | -27.9x | |
$3.6B | n/a | n/a | |
$3.5B | n/a | n/a | |
$3.4B | 11.2x | -29.0x | |
$3.4B | 2.5x | 9.4x | |
$3.3B | 7.2x | 23.3x | |
$3.3B | 8.9x | 27.0x | |
$3.3B | 36.6x | -1377.3x | |
$3.2B | 2.4x | 7.0x | |
$3.2B | 3.8x | 14.2x | |
$3.2B | n/a | n/a | |
$3.1B | 1.9x | 9.5x | |
$3.0B | 3.7x | 19.9x | |
$2.9B | n/a | n/a | |
$2.8B | 4.1x | 15.8x | |
$2.7B | 2.5x | 11.9x | |
$2.7B | n/a | n/a | |
$2.6B | 268.3x | -10.2x | |
$2.5B | 6.9x | 42.9x | |
$2.5B | 2.2x | 10.9x | |
$2.4B | 4.1x | 15.3x | |
$2.4B | n/a | n/a | |
$2.4B | 8.3x | 16.5x | |
$2.3B | 5.9x | 13.7x | |
$2.2B | 2.9x | 16.6x | |
$2.2B | 3.4x | 8.4x | |
$2.1B | 18.7x | -30.5x | |
$2.1B | 2.9x | 15.5x | |
$2.1B | 5.4x | 15.0x | |
$2.1B | 38.7x | -138.9x | |
$1.9B | 6.7x | -12.2x | |
$1.8B | 2.7x | 10.7x | |
$1.8B | 297.6x | n/a | |
$1.8B | 13.0x | 31.5x | |
$1.8B | 4.6x | 13.0x | |
$1.8B | 12.6x | -19.8x | |
$1.7B | 10.9x | -25.8x | |
$1.7B | 2.5x | -72.3x | |
$1.6B | 3.3x | -261.1x | |
$1.6B | 3.9x | 19.5x | |
$1.6B | 2.4x | 3.9x | |
$1.6B | 6.5x | -15.1x | |
$1.5B | 2.1x | 5.5x | |
$1.5B | 3.9x | 15.7x | |
$1.5B | 19.5x | 49.7x | |
$1.4B | 2.5x | 9.8x | |
$1.4B | 5.4x | -16.3x | |
$1.4B | 1.2x | 4.7x | |
$1.4B | 0.6x | 3.8x | |
$1.4B | 2.1x | 8.0x | |
$1.3B | 6.5x | 38.0x | |
$1.3B | 1.4x | 5.8x | |
$1.3B | 35.9x | n/a | |
$1.3B | 9.4x | n/a | |
$1.3B | 11.4x | -24.7x | |
$1.2B | 2.6x | 18.8x | |
$1.2B | n/a | n/a | |
$1.2B | 90.0x | n/a | |
$1.2B | 0.5x | n/a | |
$1.2B | 21.5x | -12.4x | |
$1.2B | 3.2x | n/a | |
$1.1B | 2.9x | 12.6x | |
$1.1B | 4.9x | 20.7x | |
$1.1B | n/a | n/a | |
$1.1B | 1.6x | -7.2x | |
$1.0B | n/a | n/a | |
$1.0B | n/a | n/a | |
$995M | 4.5x | 76.3x | |
$992M | 19.6x | n/a | |
$965M | 9.4x | 284.7x | |
$941M | 5.2x | 20.4x | |
$941M | n/a | -5.8x | |
$941M | n/a | n/a | |
$904M | 9.3x | 17.7x | |
$894M | n/a | n/a | |
$863M | 3.3x | 5.5x | |
$863M | 7.8x | 11.8x | |
$858M | n/a | n/a | |
$836M | 0.9x | 4.9x | |
$822M | 3.4x | n/a | |
$810M | 4.0x | 362.8x | |
$789M | n/a | n/a | |
$788M | 4.5x | 21.9x | |
$787M | n/a | -4.1x | |
$780M | 2.6x | 19.9x | |
$765M | 8.4x | -5.5x | |
$759M | 1.2x | 6.4x | |
$758M | n/a | -9.2x | |
$752M | 2.2x | -47.3x | |
$735M | n/a | -3.5x | |
$731M | n/a | n/a | |
$725M | 6.7x | 31.8x | |
$708M | 843.2x | -7.3x | |
$691M | 263524.7x | -6.0x | |
$691M | n/a | n/a | |
$683M | 2.2x | -379.6x | |
$679M | 1.5x | 7.1x | |
$672M | 1.8x | 13.2x | |
$664M | 31.5x | -245.7x | |
$626M | n/a | n/a | |
$624M | 2.5x | 10.6x | |
$622M | 244.3x | -9.3x | |
$601M | 6.2x | 26.8x | |
$601M | 1.9x | 5.9x | |
$590M | 3.4x | n/a | |
$570M | n/a | n/a | |
$564M | n/a | -3.3x | |
$562M | 6.6x | -4.4x | |
$537M | n/a | -1.5x | |
$516M | n/a | n/a | |
$499M | 2979.6x | -3.2x | |
$494M | n/a | n/a | |
$493M | 457.5x | -24.3x | |
$492M | 23.3x | 172.3x | |
$489M | 78.8x | n/a | |
$483M | 7.8x | 31.8x | |
$482M | 4.9x | 14.1x | |
$464M | 47.0x | -15.5x | |
$461M | n/a | n/a | |
$452M | 34.0x | -4.2x | |
$450M | n/a | n/a | |
$448M | n/a | -2.1x | |
$448M | 6.3x | -24.0x | |
$433M | 74.2x | -1.9x | |
$432M | n/a | -4.9x | |
$429M | 46.9x | -11.5x | |
$427M | 1.3x | 5.7x | |
$391M | n/a | -1.7x | |
$378M | 3.4x | -42.0x | |
$363M | 9.4x | -27.9x | |
$362M | 6.4x | -1.0x | |
$354M | 3.5x | -3.5x | |
$350M | 33.1x | -2.0x | |
$343M | n/a | n/a | |
$338M | 1.0x | 9.0x | |
$332M | 62.2x | n/a | |
$330M | 4.3x | 16.4x | |
$330M | 1.9x | 9.0x | |
$324M | 1.2x | 8.2x | |
$322M | 5.7x | 22.7x | |
$321M | n/a | n/a | |
$316M | 0.8x | 7.1x | |
$313M | 22021.7x | -2.9x | |
$296M | 1.9x | 8.4x | |
$295M | 29.1x | n/a | |
$291M | n/a | -2.7x | |
$288M | 7.3x | 33.7x | |
$274M | n/a | n/a | |
$273M | n/a | n/a | |
$273M | 3.8x | -3.5x | |
$272M | n/a | -2.1x | |
$271M | n/a | n/a | |
$263M | 2.0x | 4.0x | |
$262M | 2.4x | -26.5x | |
$260M | n/a | n/a | |
$249M | 11.0x | -4.4x | |
$247M | n/a | n/a | |
$230M | 3.6x | 7.0x | |
$225M | n/a | n/a | |
$222M | 2.4x | -1.0x | |
$222M | 1.3x | -2.0x | |
$222M | n/a | -2.2x | |
$220M | n/a | n/a | |
$218M | n/a | -1.9x | |
$205M | 3.1x | n/a | |
$205M | 3.9x | -7.9x | |
$197M | 2.1x | 6.7x | |
$185M | 10.8x | 20.6x | |
$180M | n/a | n/a | |
$177M | n/a | -1.2x | |
$175M | 1.6x | -0.9x | |
$175M | 1.4x | 14.7x | |
$175M | n/a | n/a | |
$173M | n/a | n/a | |
$172M | 1.2x | -0.9x | |
$170M | 47.6x | -4.6x | |
$169M | 31.9x | -3.8x | |
$168M | 19.8x | -6.9x | |
$164M | 3.4x | 13.5x | |
$152M | 3.4x | 27.8x | |
$151M | n/a | n/a | |
$150M | 6.0x | -3.5x | |
$150M | 61.3x | n/a | |
$149M | 24.0x | -3.1x | |
$148M | 55.7x | -0.7x | |
$147M | 1.1x | -1.4x | |
$147M | n/a | n/a | |
$147M | n/a | -4.5x | |
$146M | n/a | n/a | |
$132M | n/a | n/a | |
$130M | n/a | -0.7x | |
$128M | n/a | n/a | |
$122M | 1.4x | -3.6x | |
$119M | 6.2x | 19.5x | |
$117M | 17.1x | -3.6x | |
$114M | 276.2x | -8.1x | |
$106M | n/a | n/a | |
$104M | 7.7x | n/a | |
$103M | 1.8x | 11.2x | |
$102M | 1.6x | n/a | |
$99.2M | 4.3x | -0.6x | |
$98.9M | n/a | n/a | |
$93.9M | n/a | n/a | |
$91.8M | 23.2x | -2.8x | |
$91.6M | 3.2x | 13.3x | |
$87.6M | 1.5x | 18.3x | |
$87.1M | n/a | -0.9x | |
$86.1M | n/a | -3.2x | |
$82.1M | n/a | n/a | |
$81.3M | n/a | -1.0x | |
$80.3M | 17.1x | n/a | |
$71.2M | n/a | n/a | |
$69.1M | n/a | n/a | |
$66.5M | n/a | n/a | |
$62.1M | n/a | n/a | |
$61.2M | 0.8x | 7.3x | |
$59.0M | n/a | n/a | |
$56.1M | n/a | n/a | |
$54.1M | 13.8x | -39.6x | |
$49.1M | 1.4x | -14.7x | |
$48.3M | 2.1x | -0.4x | |
$46.5M | 13.9x | -5.7x | |
$45.2M | 8.6x | -4.6x | |
$45.1M | 9.3x | -1.8x | |
$41.1M | n/a | -1.9x | |
$40.3M | n/a | n/a | |
$39.8M | n/a | n/a | |
$38.9M | 7.4x | -1.4x | |
$38.3M | n/a | n/a | |
$38.1M | n/a | n/a | |
$37.8M | n/a | n/a | |
$36.7M | 72.6x | -2.1x | |
$35.6M | 17.0x | -0.3x | |
$34.7M | 1.4x | -0.3x | |
$33.3M | 10.4x | -8.9x | |
$33.3M | n/a | n/a | |
$33.1M | 2.3x | -19.4x | |
$32.6M | 1.3x | 8.1x | |
$32.5M | n/a | -5.8x | |
$31.8M | n/a | n/a | |
$30.7M | n/a | n/a | |
$30.7M | n/a | n/a | |
$30.5M | 7.6x | -0.2x | |
$30.5M | n/a | n/a | |
$28.9M | n/a | -0.3x | |
$28.9M | 5.1x | 12.8x | |
$27.7M | n/a | n/a | |
$27.7M | 6.2x | n/a | |
$27.1M | n/a | n/a | |
$25.9M | n/a | n/a | |
$25.3M | 37.4x | -3.2x | |
$24.6M | n/a | n/a | |
$24.4M | 15.3x | -35.5x | |
$24.2M | n/a | n/a | |
$23.7M | n/a | -2.3x | |
$22.5M | n/a | n/a | |
$21.7M | n/a | n/a | |
$21.5M | n/a | -13.1x | |
$21.2M | n/a | n/a | |
$20.7M | 27.3x | -25.7x | |
$20.6M | n/a | n/a | |
$18.7M | n/a | n/a | |
$18.4M | 70.2x | -10.3x | |
$17.6M | 4.7x | -1.8x | |
$16.9M | n/a | n/a | |
$16.7M | n/a | n/a | |
$16.2M | n/a | n/a | |
$16.1M | n/a | n/a | |
$16.0M | 15.6x | -9.5x | |
$16.0M | n/a | n/a | |
$15.7M | 12.2x | -24.8x | |
$15.6M | 36.2x | -1.4x | |
$15.4M | n/a | n/a | |
$15.3M | 10.9x | -13.2x | |
$15.2M | 4.4x | n/a | |
$14.7M | n/a | n/a | |
$12.9M | 2.1x | 6.4x | |
$12.6M | n/a | n/a | |
$12.5M | n/a | n/a | |
$12.3M | n/a | n/a | |
$11.1M | n/a | n/a | |
$10.9M | n/a | n/a | |
$10.3M | n/a | -3.1x | |
$9.1M | 3.2x | -2.4x | |
$8.7M | 3.9x | -0.4x | |
$8.4M | n/a | n/a | |
$8.4M | n/a | -2.7x | |
$8.1M | 1.1x | -0.6x | |
$7.8M | n/a | n/a | |
$7.6M | n/a | n/a | |
$7.4M | n/a | n/a | |
$7.3M | n/a | n/a | |
$7.2M | n/a | n/a | |
$6.9M | n/a | n/a | |
$6.8M | 0.3x | -0.3x | |
$6.8M | n/a | n/a | |
$6.7M | n/a | n/a | |
$6.6M | n/a | n/a | |
$6.6M | 5.1x | -2.8x | |
$6.1M | n/a | -2.8x | |
$6.0M | 1.7x | -2.8x | |
$5.8M | n/a | n/a | |
$5.7M | n/a | n/a | |
$5.5M | 1.0x | -1.8x | |
$5.3M | 4.1x | -1.3x | |
$5.1M | n/a | n/a | |
$5.0M | n/a | n/a | |
$4.8M | n/a | n/a | |
$4.8M | 2.7x | n/a | |
$4.8M | 5.0x | -0.4x | |
$4.6M | n/a | n/a | |
$4.6M | n/a | -1.2x | |
$4.6M | n/a | n/a | |
$4.6M | n/a | n/a | |
$4.6M | n/a | n/a | |
$4.3M | n/a | -0.4x | |
$4.2M | n/a | n/a | |
$4.2M | n/a | -2.1x | |
$4.1M | n/a | n/a | |
$3.9M | n/a | n/a | |
$3.8M | n/a | n/a | |
$3.6M | n/a | n/a | |
$3.6M | n/a | n/a | |
$3.5M | 16.8x | -1.1x | |
$3.4M | n/a | -2.4x | |
$3.3M | n/a | n/a | |
$2.6M | n/a | n/a | |
$1.9M | 0.0x | -0.0x | |
$1.9M | n/a | -7.6x | |
$1.8M | n/a | n/a | |
$1.5M | n/a | n/a | |
$1.4M | n/a | n/a | |
$1.2M | n/a | n/a | |
$1.1M | n/a | n/a | |
$1.0M | 0.0x | -0.0x | |
$0.9M | 1.0x | -0.3x | |
$0.8M | 0.0x | n/a | |
$0.7M | n/a | n/a | |
$0.6M | 0.1x | 1.2x | |
$0.5M | n/a | n/a | |
$0.2M | n/a | n/a | |
-$0.2M | n/a | n/a | |
-$0.5M | n/a | n/a | |
-$0.8M | n/a | n/a | |
-$1.4M | n/a | n/a | |
-$2.6M | n/a | n/a | |
-$3.0M | -3.6x | n/a | |
-$6.6M | n/a | n/a | |
-$6.9M | -214.8x | 0.6x | |
-$7.4M | n/a | 0.1x | |
-$9.1M | n/a | n/a | |
-$10.7M | -1.1x | n/a | |
-$11.4M | -5.6x | 0.6x | |
-$14.3M | -4.8x | 0.2x | |
-$14.7M | -22.7x | 0.2x | |
-$14.9M | -6.1x | n/a | |
-$19.0M | -0.1x | 0.1x | |
-$20.5M | n/a | n/a | |
-$21.7M | -2.7x | 0.5x | |
-$25.5M | -6.6x | 0.4x | |
-$25.9M | -32.0x | 0.3x | |
-$31.3M | n/a | n/a | |
-$36.2M | n/a | 0.8x | |
-$37.8M | n/a | n/a | |
-$50.5M | -5.3x | n/a | |
-$57.9M | -98.8x | n/a | |
-$61.2M | -0.3x | 0.8x | |
-$64.6M | n/a | n/a | |
-$69.5M | -16.8x | 0.5x | |
-$70.1M | -1.9x | n/a | |
-$79.8M | n/a | 0.7x | |
-$91.0M | n/a | 0.5x | |
-$99.9M | -45.4x | 1.8x | |
-$105M | n/a | 0.6x | |
-$113M | n/a | 0.8x | |
-$121M | -4.7x | 0.6x | |
-$146M | -101.1x | 0.7x | |
-$161M | -262.7x | 0.8x | |
-$167M | -461.0x | 2.3x | |
-$178M | -16.6x | 0.5x | |
-$203M | -3.0x | 1.2x | |
-$231M | n/a | n/a | |
-$2.0B | -6.1x | 11.4x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Biopharmaceuticals